These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 17927495)

  • 1. Lycopene and soy isoflavones in the treatment of prostate cancer.
    Vaishampayan U; Hussain M; Banerjee M; Seren S; Sarkar FH; Fontana J; Forman JD; Cher ML; Powell I; Pontes JE; Kucuk O
    Nutr Cancer; 2007; 59(1):1-7. PubMed ID: 17927495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soy isoflavones in the treatment of prostate cancer.
    Hussain M; Banerjee M; Sarkar FH; Djuric Z; Pollak MN; Doerge D; Fontana J; Chinni S; Davis J; Forman J; Wood DP; Kucuk O
    Nutr Cancer; 2003; 47(2):111-7. PubMed ID: 15087261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia.
    Fischer L; Mahoney C; Jeffcoat AR; Koch MA; Thomas BE; Valentine JL; Stinchcombe T; Boan J; Crowell JA; Zeisel SH
    Nutr Cancer; 2004; 48(2):160-70. PubMed ID: 15231450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk.
    Bunker CH; McDonald AC; Evans RW; de la Rosa N; Boumosleh JM; Patrick AL
    Nutr Cancer; 2007; 57(2):130-7. PubMed ID: 17571945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The specific role of isoflavones in reducing prostate cancer risk.
    Kumar NB; Cantor A; Allen K; Riccardi D; Besterman-Dahan K; Seigne J; Helal M; Salup R; Pow-Sang J
    Prostate; 2004 May; 59(2):141-7. PubMed ID: 15042614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen.
    Ide H; Tokiwa S; Sakamaki K; Nishio K; Isotani S; Muto S; Hama T; Masuda H; Horie S
    Prostate; 2010 Jul; 70(10):1127-33. PubMed ID: 20503397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial.
    Adams KF; Chen C; Newton KM; Potter JD; Lampe JW
    Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):644-8. PubMed ID: 15066931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men.
    Maskarinec G; Morimoto Y; Hebshi S; Sharma S; Franke AA; Stanczyk FZ
    Eur J Clin Nutr; 2006 Dec; 60(12):1423-9. PubMed ID: 16775579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer.
    Dalais FS; Meliala A; Wattanapenpaiboon N; Frydenberg M; Suter DA; Thomson WK; Wahlqvist ML
    Urology; 2004 Sep; 64(3):510-5. PubMed ID: 15351581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen.
    Grainger EM; Schwartz SJ; Wang S; Unlu NZ; Boileau TW; Ferketich AK; Monk JP; Gong MC; Bahnson RR; DeGroff VL; Clinton SK
    Nutr Cancer; 2008; 60(2):145-54. PubMed ID: 18444145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
    Ansari MS; Gupta NP
    Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
    Clark PE; Hall MC; Borden LS; Miller AA; Hu JJ; Lee WR; Stindt D; D'Agostino R; Lovato J; Harmon M; Torti FM
    Urology; 2006 Jun; 67(6):1257-61. PubMed ID: 16765186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
    Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
    Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men.
    Jenkins DJ; Kendall CW; D'Costa MA; Jackson CJ; Vidgen E; Singer W; Silverman JA; Koumbridis G; Honey J; Rao AV; Fleshner N; Klotz L
    J Urol; 2003 Feb; 169(2):507-11. PubMed ID: 12544298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
    Pantuck AJ; Leppert JT; Zomorodian N; Aronson W; Hong J; Barnard RJ; Seeram N; Liker H; Wang H; Elashoff R; Heber D; Aviram M; Ignarro L; Belldegrun A
    Clin Cancer Res; 2006 Jul; 12(13):4018-26. PubMed ID: 16818701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones.
    Jarred RA; Keikha M; Dowling C; McPherson SJ; Clare AM; Husband AJ; Pedersen JS; Frydenberg M; Risbridger GP
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1689-96. PubMed ID: 12496063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
    Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
    Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
    BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.